신경병성 안구 통증(NOP) : 시장 인사이트, 역학 및 시장 예측(2036년)

Neuropathic Ocular Pain (NOP) Insights and Trends

• Neuropathic Ocular Pain (NOP) market is witnessing strong growth across the leading markets, including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, during the study period, driven by rising awareness of chronic ocular pain disorders, improved diagnostic capabilities, and the growing demand for targeted therapies addressing neuropathic mechanisms.
• According to National Organization for Rare Disorders (NORD) (2025), the exact number of people affected by NOP is not known yet.
• The proportion of females affected by NOP is higher than that of males, and women also tend to experience a greater incidence of associated conditions such as fibromyalgia and autoimmune diseases.
• Autoimmune diseases affect approximately 5-8% of the population, with nearly 78% of affected individuals being women, which may contribute to the higher incidence of ocular neuropathic pain observed in females.
• The treatment of NOP primarily involves symptomatic and supportive approaches such as lubricating eye drops, topical anti-inflammatory agents, autologous serum tears, corticosteroids, and systemic neuropathic pain medications to reduce ocular discomfort, inflammation, and nerve sensitization, although treatment responses remain variable and limited in many patients.
• Currently, there are no FDA approved therapies specifically for NOP. The pipeline remains limited, with key players such as OKYO Pharma developing urcosimod (0.05%; OK-101), while ongoing research continues to explore novel anti-inflammatory, neuroprotective, and pain-modulating therapies for chronic ocular neuropathic pain.

DelveInsight's 'Neuropathic Ocular Pain (NOP)- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the NOP, historical and forecasted epidemiology, as well as the NOP market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The NOP market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, NOP patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in NOP and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Neuropathic Ocular Pain (NOP) Market

• Rising NOP Incidence

The increasing incidence of NOP, particularly among females, is a primary driver of NOP market expansion, supported by growing awareness of chronic ocular pain disorders, improved diagnostic capabilities, rising prevalence of dry eye disease and autoimmune conditions, and ongoing development of targeted therapeutic approaches.

• Rising Opportunities in Targeted NOP Therapies

Growing understanding of neuro-inflammation and corneal nerve dysfunction in NOP is driving opportunities for targeted therapies aimed at reducing chronic ocular pain and improving nerve health, with emerging agents such as Urcosimod (0.05%; OK-101) by OKYO Pharma highlighting progress in disease-specific treatment development.

• Emerging NOP Competitive Landscape

The pipeline for NOP remains limited, with no approved targeted therapies currently available. Some of the ACLF drugs in clinical development include urcosimod (0.05%; OK-101), and others.

Neuropathic Ocular Pain (NOP) Understanding and Treatment Algorithm

Neuropathic Ocular Pain (NOP) Overview and Diagnosis

NOP is a chronic ocular pain condition caused by damage or dysfunction of the corneal nerves and somatosensory pathways, often occurring in the absence of significant visible ocular surface abnormalities. The condition is characterized by symptoms such as burning, stinging, dryness, photophobia, foreign body sensation, and severe eye discomfort, frequently associated with dry eye disease, refractive surgery, infections, trauma, autoimmune disorders, or systemic neuropathic conditions. NOP can significantly impair quality of life and is often difficult to diagnose and manage due to the overlap of symptoms with other ocular surface disorders and the complex underlying neuro-inflammatory mechanisms.

NOP is diagnosed through clinical evaluation, patient history, and exclusion of other ocular surface disorders. Diagnostic workup includes ocular surface examination, corneal sensitivity assessment, tear film evaluation, fluorescein staining, and specialized tests such as confocal microscopy or topical anesthetic challenge to identify corneal nerve dysfunction and pain sensitization.

Neuropathic Ocular Pain (NOP) Treatment

The primary goals of NOP treatment are to reduce ocular pain, control neuro-inflammation, improve corneal nerve function, and restore ocular surface health. The current management includes artificial tears, corticosteroids, cyclosporine, lifitegrast, autologous serum tears, and systemic neuromodulators such as gabapentin and pregabalin for refractory pain. Emerging targeted therapies such as Urcosimod (0.05%; OK-101) by OKYO Pharma are being developed to address the underlying inflammatory and neuropathic mechanisms of disease.

Neuropathic Ocular Pain (NOP) Unmet Needs

The section "unmet needs of NOP" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Delayed and challenging diagnosis due to symptom overlap with dry eye disease and other ocular disorders

2. Limited disease-specific therapies targeting underlying neuropathic mechanisms

3. Persistent chronic ocular pain despite conventional dry eye treatments

4. Poor understanding of disease pathophysiology and heterogeneity, and others.....

Neuropathic Ocular Pain (NOP) Epidemiology

Key Findings from Neuropathic Ocular Pain (NOP) Epidemiological Analysis and Forecast

• NOP is increasingly recognized among patients with chronic ocular pain and dry eye like symptoms, with variations in disease burden, diagnosis, and clinical presentation across different patient populations and regions.
• In 2025, the United States accounted for the highest number of NOP cases among the 7MM, and this number is expected to increase throughout the study period.
• The observed female predominance and earlier onset of NOP highlight the importance of early diagnosis, gender-specific risk assessment, and targeted therapeutic strategies to improve disease management and patient outcomes.

Neuropathic Ocular Pain (NOP) Drug Chapters & Competitive Analysis

The NOP drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the NOP treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the NOP therapeutics market.

Approved Therapies for Neuropathic Ocular Pain (NOP)

NOP remains a significant unmet need due to the absence of approved disease-specific therapies and the limited effectiveness of current symptomatic treatments, creating substantial opportunities for novel therapeutic development and future research advancements.

Neuropathic Ocular Pain (NOP) Pipeline Analysis

Urcosimod (0.05%; OK-101): OKYO Pharma

Urcosimod (0.05%) is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor on ocular immune and nerve-related cells, developed for dry eye disease and neuropathic corneal pain. It has demonstrated anti-inflammatory and pain-reducing effects in preclinical models and showed significant efficacy in Phase II clinical trials for both neuropathic corneal pain and dry eye disease. The drug has received the first FDA IND and Fast Track designation for the treatment of Neuropathic Corneal Pain (NCP).

As per company's 2026 corporate presentation, a Phase IIb/III multiple-dose study planned to initiate this year, with the topline results anticipated in H1 2027.

Neuropathic Ocular Pain (NOP) Key Players, Market Leaders and Emerging Companies

OKYO Pharma, and others

Neuropathic Ocular Pain (NOP) Drug Updates

• In March 2026, OKYO Pharma Limited reported positive Phase IIa exploratory results for urcosimod (0.05%) in NCP. The study showed clinically meaningful pain reduction, improved quality of life, and potential corneal nerve restoration signals versus placebo after 12 weeks of treatment. The findings will be presented at the 2026 ARVO Annual Meeting.
• In January 2026, OKYO Pharma announced FDA authorization of a compassionate-use IND application for urcosimod (0.05%) to treat a patient with severe NCP who had limited treatment options and no approved therapies available.
• In December 2025, OKYO Pharma reported that patients treated with urcosimod (0.05%) in a Phase II trial for NCP showed significant pain reduction along with favorable improvements in corneal nerve structure compared with placebo.
• In September 2025, OKYO Pharma announced plans to advance urcosimod into a multiple-ascending-dose Phase II trial for NCP following positive proof-of-concept results showing over 80% pain reduction in 75% of treated patients, while also progressing discussions with the FDA under Fast-Track designation for future registration studies.

Drug Class Insights

Neuropathic Ocular Pain (NOP) Market Outlook

The NOP market is undergoing a gradual transformation, shifting from conventional symptomatic management toward targeted therapies addressing the underlying neuropathic and inflammatory mechanisms of ocular pain. Current treatment approaches primarily rely on artificial tears, topical corticosteroids, autologous serum tears, anti-inflammatory agents, systemic neuropathic pain medications, and supportive therapies, which often provide limited or temporary symptomatic relief without addressing the underlying corneal nerve dysfunction. Currently, there are no FDA approved therapies specifically for NOP, this creates substantial opportunities for emerging pipeline products and expedited regulatory pathways. Emerging therapies focused on reducing inflammation, modulating nerve signaling, and improving corneal nerve health are expected to reshape the treatment landscape and strengthen clinical and regulatory interest in novel ophthalmic pain therapies.

The advancement of urcosimod (0.05%; OK-101) by OKYO Pharma highlights the growing focus on targeted therapies for NOP, with Phase II data demonstrating promising anti-inflammatory and pain-reducing efficacy in patients with limited treatment options.

Overall, increasing research into ocular neuro-inflammation, advancements in corneal imaging and diagnostic technologies, growing awareness of chronic ocular pain disorders, and the emergence of targeted pipeline therapies are expected to drive growth in the NOP market during the forecast period, creating significant commercial opportunities for both established ophthalmology companies and emerging biotech innovators.

• According to the estimates, the United States accounted for the largest share of the NOP market among the major markets during the study period.
• The NOP market is evolving as treatment focus shifts from conventional symptomatic management toward targeted therapies addressing neuro-inflammation, corneal nerve dysfunction, and neuropathic pain mechanisms, with emerging candidates such as urcosimod (OK-101) driving interest due to their potential to provide effective long-term pain relief and disease-specific treatment benefits.
• Regional market dynamics show the US leading in research activity and commercial potential, while Europe and Japan are witnessing increasing clinical interest driven by rising awareness of chronic ocular pain disorders, improved diagnostic capabilities, and ongoing development of novel ophthalmic therapies.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Neuropathic Ocular Pain (NOP) (2022-2036 Forecast)

The NOP market comprises chemR23 agonists and anti-inflammatory peptide therapies, calcineurin inhibitors and T-cell mediated inflammation modulators, Nerve Growth Factor (NGF) stimulators and regenerative therapies, neuromodulators and central pain signaling inhibitors, and topical anti-inflammatory and corticosteroid therapies, with multiple drug classes targeting neuro-inflammation, corneal nerve dysfunction, chronic ocular pain, and central sensitization associated with NOP.

• ChemR23 agonists and anti-inflammatory peptide therapies: These therapies are designed to reduce ocular inflammation and neuropathic pain by modulating ChemR23-mediated inflammatory signaling and corneal nerve activity. Representative therapies include Urcosimod (0.05%) by OKYO Pharma.
• Calcineurin inhibitors and T-cell mediated inflammation modulators: These therapies aim to suppress ocular surface inflammation, reduce immune-mediated corneal damage, and improve tear film stability. Key therapies include cyclosporine ophthalmic solutions (RESTASIS, CEQUA) and lifitegrast (XIIDRA).
• Nerve growth factor (NGF) stimulators and regenerative therapies: These approaches focus on promoting corneal nerve regeneration, improving epithelial healing, and restoring ocular surface integrity. Representative therapies include cenegermin (OXERVATE), autologous serum tears, and platelet-rich plasma (PRP) eye drops.

Conventional lubricants, anti-inflammatory eye drops, and systemic neuropathic pain therapies currently dominate the NOP treatment landscape, while targeted regenerative and neuroprotective therapies are driving future innovation aimed at addressing the underlying neuropathic mechanisms of disease.

Neuropathic Ocular Pain (NOP) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the NOP market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in NOP is expected to vary across conventional ocular surface treatments, systemic neuropathic pain therapies, and emerging targeted ophthalmic agents. Existing therapies such as lubricating eye drops, corticosteroids, cyclosporine formulations, and systemic neuromodulators currently account for the highest uptake despite their limited disease-specific efficacy. Among emerging therapies, urcosimod (0.05%; OK-101) is anticipated to witness relatively stronger future uptake owing to its anti-inflammatory and pain-reducing potential demonstrated in Phase II studies, while regenerative therapies such as autologous serum tears, platelet-rich plasma (PRP) eye drops, and nerve-regenerative approaches are expected to gain gradual adoption as clinical evidence and physician awareness continue to expand.

Market Access and Reimbursement of NOP

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Neuropathic Ocular Pain (NOP) Therapies Price Scenario & Trends

Pricing and analogue assessment of NOP therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Neuropathic Ocular Pain (NOP)

To keep up with NOP market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the NOP emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in NOP, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of Mississippi Medical Center, University of Bologna, and Teikyo University School of Medicine, etc. were contacted. Their opinion helps understand and validate current and emerging NOP therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in NOP.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Neuropathic Ocular Pain (NOP), strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of NOP, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the NOP market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM NOP market.

Report Insights

• Neuropathic Ocular Pain (NOP) Patient Population Forecast
• Neuropathic Ocular Pain (NOP) Therapeutics Market Size
• Neuropathic Ocular Pain (NOP) Pipeline Analysis
• Neuropathic Ocular Pain (NOP) Market Size and Trends
• Neuropathic Ocular Pain (NOP) Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Neuropathic Ocular Pain (NOP) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Neuropathic Ocular Pain (NOP) Treatment Addressable Market (TAM)
• Neuropathic Ocular Pain (NOP) Competitive Landscape
• Neuropathic Ocular Pain (NOP) Major Companies Insights
• Neuropathic Ocular Pain (NOP) Price Trends and Analogue Assessment
• Neuropathic Ocular Pain (NOP) Therapies Drug Adoption/Uptake
• Neuropathic Ocular Pain (NOP) Therapies Peak Patient Share analysis

Report Assessment

• Neuropathic Ocular Pain (NOP) Current Treatment Practices
• Neuropathic Ocular Pain (NOP) Unmet Needs
• Neuropathic Ocular Pain (NOP) Clinical Development Analysis
• Neuropathic Ocular Pain (NOP) Emerging Drugs Product Profiles
• Neuropathic Ocular Pain (NOP) Market Attractiveness
• Neuropathic Ocular Pain (NOP) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Neuropathic Ocular Pain (NOP) market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Neuropathic Ocular Pain (NOP)?
• What are the disease risks, burdens, and unmet needs of Neuropathic Ocular Pain (NOP)? What will be the growth opportunities across the 7MM concerning the patient population with Neuropathic Ocular Pain (NOP)?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Neuropathic Ocular Pain (NOP)? What are the current guidelines for treating Neuropathic Ocular Pain (NOP) in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Neuropathic Ocular Pain (NOP) market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Neuropathic Ocular Pain (NOP)

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Neuropathic Ocular Pain (NOP) Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of NOP By Therapies in the 7MM, in 2026
• 6.3. Market Share (%) Distribution of NOP By Therapies in the 7MM, in 2036

7. Disease Background and Overview of Neuropathic Ocular Pain (NOP)

• 7.1. Introduction
• 7.2. Causes and Risk Factors of Neuropathic Ocular Pain
• 7.3. Signs and Symptoms
• 7.4. Pathophysiology
• 7.5. Biomarkers
• 7.6. Diagnosis
• 7.7. Diagnostic Algorithm
  • 7.7.1. Differential Diagnosis
  • 7.7.2. Diagnosis Guidelines

8. Treatment of Neuropathic Ocular Pain (NOP)

• 8.1. Treatment Algorithm
• 8.2. Treatment Guidelines for Neuropathic Ocular Pain

9. Epidemiology and Patient Population of Neuropathic Ocular Pain (NOP)

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Cases of NOP in the 7MM
• 9.4. The United States
  • 9.4.1. Total Cases of Several Eye Disorders and Surgeries in US
  • 9.4.2. Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in US
  • 9.4.3. Total Treated Cases of Neuropathic Ocular Pain (NOP) in US
• 9.5. EU4 and the UK
  • 9.5.1. Total Cases of Several Eye Disorders and Surgeries in EU4 and the UK
  • 9.5.2. Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in EU4 and the UK
  • 9.5.3. Total Treated Cases of Neuropathic Ocular Pain (NOP) in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Cases of Several Eye Disorders and Surgeries in Japan
  • 9.6.2. Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in Japan
  • 9.6.3. Total Treated Cases of Neuropathic Ocular Pain (NOP) in Japan

10. Patient Journey of Neuropathic Ocular Pain (NOP)

11. Emerging Drugs of Neuropathic Ocular Pain (NOP)

• 11.1. Emerging Competitive Landscape of Neuropathic Ocular Pain (NOP)
• 11.2. Urcosimod (OK-101): OKYO Pharma
  • 11.2.1. Drug Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst's Views

12. Neuropathic Ocular Pain (NOP): 7MM Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Neuropathic Ocular Pain (NOP)
• 12.3. Conjoint Analysis of Neuropathic Ocular Pain (NOP)
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of NOP in the 7MM
• 12.6. Total Market Size of NOP by Therapies in the 7MM
• 12.7. The United States
  • 12.7.1. Total Market Size of NOP in the United States
  • 12.7.2. Total Market Size of NOP by Therapies in the United States
• 12.8. EU4 and the UK
  • 12.8.1. Total Market Size of NOP in EU4 and the UK
  • 12.8.2. Total Market Size of NOP by Therapies in EU4 and the UK
• 12.9. Japan
  • 12.9.1. Total Market Size of NOP in Japan
  • 12.9.2. Total Market Size of NOP by Therapies in Japan

13. Unmet Needs of Neuropathic Ocular Pain (NOP)

14. SWOT Analysis of Neuropathic Ocular Pain (NOP)

15. KOL Views of Neuropathic Ocular Pain (NOP)

16. Market Access and Reimbursement

• 16.1. The United States
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of NOP Therapies

17. KOL Views

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight